Tesla, Netflix among Monday’s market cap stock movers

  • May 5, 2025

Monday’s trading session has brought significant movements across the board, with mega-cap stocks like Apple Computer Inc (NASDAQ: AAPL ) and Tesla Motors (NASDAQ: TSLA ) experiencing notable declines. Large-cap stocks have also seen their share of volatility, with Tyson Foods (NYSE: TSN ) and Zimmer Hldgs (NYSE: ZBH ) on the downside. Here’s a rundown of today’s stock movers, with a focus on intra-day performances from mega-cap to small-cap categories.

Mega-Cap Movers:

  • Apple Computer Inc (AAPL); Apple launches four-part US dollar corporate bond sale: -3.2%
  • Tesla Motors (TSLA): -3.86%
  • Exxon Mobil (NYSE: XOM ): -2.6%
  • Netflix, inc. (NASDAQ: NFLX ): -2.25%
  • Palantir Technologies Inc (NASDAQ: PLTR ): -1.32%

Large-Cap Stock Movers:

  • Tyson Foods (TSN); Tyson Foods reports second quarter 2025 results: -9.45%
  • Zimmer Hldgs (ZBH); Zimmer Biomet shares rise as Q1 results top estimates: -9.21%
  • ON Semiconductor (NASDAQ: ON ); onsemi Reports First Quarter 2025 Results: -8.15%
  • First Solar Inc (NASDAQ: FSLR ): -5.35%
  • AngloGold Ashanti Ltd (NYSE: AU ): +4.7%

Mid-Cap Stock Movers:

  • Hipgnosis Songs (SONG): -31.03%
  • Skechers USA Inc (NYSE: SKX ): +24.84%
  • Ptc Therape (NASDAQ: PTCT ); PTC518 shows promise in Huntington’s disease trial: -18.95%
  • TG Therapeutics Inc (NASDAQ: TGTX ); TG Therapeutics Q1 revenue beats estimates, stock edges higher: -17.04%
  • NantKwest (NASDAQ: IBRX ); ImmunityBio Requests an Urgent Meeting With FDA: -12.34%

Small-Cap Stock Movers:

  • Elran Real Est (ELRE): +150.0%
  • Cantor Equity Partners Class A (CEP): -34.17%
  • Integra LifeScien (NASDAQ: IART ); Integra LifeSciences misses Q1 estimates, shares fall 4%: -29.5%
  • Aerovate Therapeutics (JBIO); Stifel initiates Jade Biosciences stock with a Buy, $19 target: -0.48%
  • Regencell Bioscience Holdings (RGC): +24.85%

For real-time, market-moving news, join Investing Pro.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.